Program v7.2.2  

Program v7.2.2 Updated

My=Program_v6.14.1  

My=Program_v6.14.1

Program_Formal_v6.14.formal1  

Acne usually begins in the teenage years and disappears after eight to 10 years. In some cases, it can persist until the 30s and even 40s. Acne is caused by inflammation of the hair follicles. It most commonly affects the face, back and chest. Features include blackheads, whiteheads, pimples (zits) …

UAT Program -BLL  

Diffusion MRI for Head and Neck Cancer  

The proposed study is to investigate the feasibility of using quantitative diffusion MRI (dMRI) methods for accurate and comprehensive assessment of treatment response. dMRI is a powerful tool to probe treatment-induced change in tumors. It is a unique in vivo imaging technique sensitive to cellular microstructures at the scale of …

Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (MA-CRC-II-018)  

The goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC.Participants will take:Induction: SHR-1701 combined with CAPOX for one cycle. Radiotherapy: Short-course radiotherapy (SCRT) (25Gy/5F). Consolidation: SHR-1701 combined with CAPOX for five cycles, after which the subjects undergo TME surgery.

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma  

The names of the study drugs and vaccine involved in this study are:DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells)Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor)Elranatamab (a type of T-cell engager antibody)

Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer (PSOAS)

Sarcopenia is a condition characterized by loss of skeletal muscle mass and function. Also, the prevalence of sarcopenia in patients with cancer is high and has a prevalence of around 25% in patients with pancreatic cancer, with a considerable impact on postoperative and survival outcomes.

A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer

Switch Maintenance in Pancreatic

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body.This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells.